JasonBlairLittenMD

Pediatric Hematology & Oncology • Poway, CA

Chief Medical Officer - Chimeric Therapeutics

Join to view full profile

Dr. Litten is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Litten's full profile

Already have an account?

Office
15023 Huntington Gate Dr92064
Poway, CA 92064
Phone+1 415-802-4360

Education & Training

University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of Miami/Jackson Health SystemResidency, Pediatrics, 2002 - 2005
Emory University School of MedicineClass of 2002

Certifications & Licensure

CA State Medical License 2020 - 2026

Clinical Trials

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Start of enrollment: 2014 Apr 01
Terminated
Phase 2

Publications & Presentations

PubMed

19 citations
Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, Jean-Frédéric Blanc, Steven A. Miles, Tom M. Ganten, Jörg Trojan
The Oncologist. 2017-07-01
2 citations
Corrections to “Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors”
J-C. Soria, F. Debraud, Ratislav Bahleda, B. Adamo, Fabrice Andre
Annals of Oncology. 2015-02-01
141 citations
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
Jean-Charles Soria, F. Debraud, Ratislav Bahleda, B. Adamo, Fabrice Andre
Annals of Oncology. 2014-11-01

Press Mentions

Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell LymphomasDecember 7th, 2020
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat CancerJune 26th, 2020
Natural Killer Biotech Artiva Launches with $78M, Industry VeteransJune 26th, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member